1 Apr

How the EPO’s latest CRISPR revocation affects the Cas9 landscape

The revocation of a Sigma-Aldrich Cas9 patent could be a sign of things to come in other EPO opposition proceedings, but Europe’s CRISPR IP state of play will remain uncertain for several years

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth